Absence of anti–HMG-CoA reductase autoantibodies in severe self-limited statin-related myopathy

James S. Floyd, Jennifer A. Brody, Eleni Tiniakou, Bruce M. Psaty, Andrew Mammen

Research output: Contribution to journalArticlepeer-review


Introduction: Patients with self-limited statin-related myopathy improve spontaneously when statins are stopped. In contrast, patients with statin-associated autoimmune myopathy have autoantibodies recognizing 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase (HMGCR) and usually require immunosuppressive therapy to control their disease. On initial presentation, it can sometimes be difficult to distinguish between these 2 diseases, as both present with muscle pain, weakness, and elevated serum creatine kinase (CK) levels. The goal of this study was to determine whether patients with severe self-limited statin-related myopathy also make anti-HMGCR autoantibodies. Methods: We screened 101 subjects with severe self-limited cerivastatin-related myopathy for anti-HMGCR autoantibodies. Results: No patient with severe self-limited cerivastatin-related myopathy had anti-HMGCR autoantibodies. Conclusion: Anti-HMGCR autoantibody testing can be used to help differentiate whether a patient has self-limited myopathy due to cerivastatin or autoimmune statin-associated myopathy; these findings may apply to other statins as well. Muscle Nerve 54: 142–144, 2016.

Original languageEnglish (US)
Pages (from-to)142-144
Number of pages3
JournalMuscle and Nerve
Issue number1
StatePublished - Jul 1 2016


  • adverse drug reaction
  • autoimmune
  • myopathy
  • rhabdomyolysis
  • statins

ASJC Scopus subject areas

  • Physiology
  • Clinical Neurology
  • Cellular and Molecular Neuroscience
  • Physiology (medical)


Dive into the research topics of 'Absence of anti–HMG-CoA reductase autoantibodies in severe self-limited statin-related myopathy'. Together they form a unique fingerprint.

Cite this